Also, the compound CAR targeting both BCMA and CS1 which has roles in myeloma parthenogenesis and specific immune cell activities, that is BC1cCAR, is able to augment the anti-tumor response compared to a single BCMA or CS1-CAR and can eliminate any BCMA−CS1+ potential relapse [60, 61]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.